Translational investigations in a cohort of 2310 patients with breast cancer from clinical trials of the German Breast Group [4] showed clinical and biological differences between HER2 completely negative (IHC0, HER2-zero) and HER2-low tumors. The gene discussed is ERBB2; the disease is breast carcinoma.